Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Allogeneic CRISPR-Cas9-Engineered T Cells (CTX110) in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)

NCT04035434 is registered in ClinicalTrials.gov with CRISPR Therapeutics AG as lead sponsor.

NCT NCT04035434
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04035434 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Allogeneic CRISPR-Cas9-Engineered T Cells (CTX110) in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)
Lead sponsor
CRISPR Therapeutics AG
Phase
Phase 1/2
Overall status
Terminated
Start date
July 22, 2019
Completion date
October 4, 2024
Enrollment
93 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

adult b cell all, b-cell lymphoma, b-cell malignancy, non-hodgkin lymphoma